Veramed expands its global footprint by acquiring Data Management, Biostatistics and Medical Writing services company Clinical Trial Data Services (CTDS)October 5, 2023
Specialist Biometrics CRO, Veramed, today announced the acquisition of Boston-based data management, biostatistics and medical writing company, CTDS. The deal will enhance Veramed’s global presence and broaden the company’s data management capability.
“The combination of CTDS and Veramed will grow our team to over 350 trusted statisticians, programmers and data managers globally and enhance our ability to provide end-to-end biometrics support. We believe that the benefits of the combination will be felt by the customers and staff of both organizations and open the door to exciting opportunities with new partners,” Matt Jones, Co-Founder and CEO of Veramed commented.
“We are excited to have joined the Veramed family and to bring together our teams of talented biostatistics, data management and medical writing experts to create a comprehensive and dynamic offering in the market,” commented Terri Sampo, Principal Consultant and Founder of CTDS.
Specialized biometrics and data management providers are proving to be an effective solution to the biotech industry's need for flexibility, speed and agility. These providers offer specialized expertise in data collection and analysis, ensure accurate results; maintain data quality and regulatory compliance; enhance resource efficiency; expedite decision-making; and provide tailored solutions to sponsor companies. Collaborating with companies like Veramed mitigates risks, provides access to advanced tools, and boosts credibility with biotech investors, contributing to more effective research, quicker decision-making, and improved prospects for funding and success.
Founded in 2005 by Terri Sampo, Clinical Trial Data Services supports small to midsize sponsor companies helping them to take the next step towards market approval for their drug or device product. CTDS’s meticulous oversight, personalized service and understanding and dedication to process is a perfect fit for Veramed’s existing reputation for quality and delivery.
“We were immediately impressed with CTDS’s core values and clear dedication to providing tailored solutions to their clients. We are confident this is a great fit and are looking forward to the future,” commented Emma Jones, Co-Founder and Executive Vice President of Statistics at Veramed.
Veramed is a high-performing partner for statistical consultancy, data management, clinical trial reporting and automation, DMC services, and evidence and value generation. It was awarded “Best Contract Research Organization – Specialist Providers” at the 18th Annual Scrip Awards in 2022 and certified as a B Corp for the first time in 2020.
The company is a pioneering CRO that is redefining intelligent healthcare decision-making. The talented Veramed team is paving the way for pharma and biotech clients by offering tailored biometrics solutions that scale and adapt as needs grow. This takes a variety of forms; from getting the basics of study design and analysis of clinical trials right, to Automation on sponsor systems, Real World Evidence, visualizations using R, and industry-leading involvement in Dataset J-SON and the OpenSource OAK project. The company works hard to customize solutions and adapt to client needs, whilst always staying true to the founding culture of promoting work-life balance for their staff and happiness within the workplace.
Veramed is an accredited B Corp and is passionate about making a difference to patient communities around the world. Being uniquely practitioner-led, the company challenges how advanced biometrics services can be used to help to move the needle on the speed, quality and effectiveness of pharma and biotech pipeline delivery. Veramed is a tech-savvy CRO that cares.
Clinical Research & Trials,
Corporate, Finance & Investor